Management of Hepatitis C: Evaluating Suitability for Drug Therapy

American Family Physician

Volumn 69, Issue 6, 2004, Pages 1429-1436+1439

  Ward, Raymond P ^a   Kugelmas, Marcelo ^b   Libsch, Karen D ^a  

^a St Mary's Family Medicine Residency   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ANEMIA; ANOREXIA; COMORBIDITY; CROHN DISEASE; DEPRESSION; DIAGNOSTIC TEST; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; ERYTHEMA; FATIGUE; FEVER; GENOTYPE; HEADACHE; HEART MUSCLE ISCHEMIA; HEPATITIS C; HUMAN; INJECTION PAIN; LIVER BIOPSY; LIVER FIBROSIS; MYALGIA; NAUSEA; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; TERATOGENICITY; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED STATES;

ALGORITHMS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; PATIENT SELECTION; UNITED STATES;

EID: 1642337979     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(3 suppl 1):62S-5S.
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
4. Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002;136:747-57.
5. Management of hepatitis C: 2002. NIH Consens State Sci Statement 2002;19:1-46.
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
7. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
8. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-12.
9. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 2003;325:135-48.
10. Velati C, Romano L, Baruffi L, Pappalettera M, Carreri V, Zanetti AR. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002;42:989-93.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
13. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):64-6.
14. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-68.
15. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
16. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
17. Day CP. Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis. Gut 2001;49:750-1.
18. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665-75.
19. Booth JC, O'Grady J, Neuberger J, the Royal College of Physicians of London, and the British Society of Gastroenterology. Clinical guidelines on the management of hepatitis C. Gut 2001;49(suppl 1):11-21.
20. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24.
21. ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. No. 220, August 1999. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999;66:307-8.
22. Chiaramonte M, Stroffolini T, Lorenzoni U, Minniti F, Conti S, Floreani A, et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol 1996;24:129-34.
23. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex Transm Infect 1998;74:399-404.
24. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9.
25. Guiding patients through chronic hepatitis C therapy. Kenilworth, N.J.: Schering Corp., 2002.
26. Management of hepatitis C. NIH Consens Statement 1997;15:1-41.